Recently, Lunan Pharmaceutical Group Pinchimontelukast Sodium Tablets (specification: 10mg) was approved by the State Drug Administration and passed the consistency evaluation of the quality and efficacy of generic drugs.
According to reports, montelukast sodium is an oral and effective selective leukotriene receptor antagonist, which is effective against cysteinyl leukotriene. The alkene (CysLT1) receptor has high affinity and selectivity, and can inhibit the physiological effect of LTD4 binding to the CysLT1 receptor without any receptor agonistic activity. It is suitable for the prevention and treatment of asthma in adults aged 15 years and older. Long-term treatment and relief of symptoms caused by seasonal allergic rhinitis and perennial allergic rhinitis in adults 15 years of age and older.
Previously, Lunan Pharmaceutical’s Pingqi chewable tablet type has passed the consistency evaluation and is suitable for the prevention and long-term treatment of asthma in children aged 2 to 14 years, as well as the relief of seasonal allergies in children aged 2 to 14 years Symptoms caused by allergic rhinitis and perennial allergic rhinitis.
Qilu Yidian correspondent Ai Liyao